A systematic review and economic model of the effectiveness and ...

91. Stein MA, Blondis TA, Schnitzler ER, O’Brien T,
Fishkin J, Blackwell B, et al. Methylphenidate
dosing: twice daily versus three times daily.
Pediatrics 1996;98:748–56.
92. Stein MA, Sarampote CS, Waldman ID, Robb AS,
Conlon C, Pearl PL, et al. A dose–response study of
OROS methylphenidate in children with attentiondeficit/hyperactivity
disorder. Pediatrics
2003;112:E404–13.
93. Tervo RC, Azuma S, Fogas B, Fiechtner H.
Children with ADHD and motor dysfunction
compared with children with ADHD only. Dev Med
Child Neurol 2002;44:383–90.
94. Weiss M, Tannock R, Kratochvil C, Dunn D,
Velez-Borras J, Thomason C, et al. A randomized,
placebo-controlled study of once-daily atomoxetine in the
school setting in children with ADHD. A submission to
the National Institute for Clinical Excellence.
Indianapolis, IN: Lilley Research Laboratories;
2004.
95. Wernicke JF, Adler L, Spencer T, West SA,
Allen AJ, Heiligenstein J, et al. Changes in
symptoms and adverse events after
discontinuation of atomoxetine in children and
adults with attention deficit/hyperactivity disorder:
a prospective, placebo-controlled assessment.
J Clin Psychopharmacol 2004;24:30–5.
96. Werry JS, Aman MG, Diamond E. Imipramine and
methylphenidate in hyperactive children. J Child
Psychol Psychiatry 1980;21:27–35.
97. Wolraich ML, Greenhill LL, Pelham W, Swanson J,
Wilens T, Palumbo D, et al. Randomized,
controlled trial of OROS methylphenidate once a
day in children with attention-deficit/hyperactivity
disorder. Pediatrics 2001;108:883–92.
98. Zeiner P, Bryhn G, Bjercke C, Truyen K, Strand G.
Response to methylphenidate in boys with
attention-deficit hyperactivity disorder. Acta
Paediatr 1999;88:298–303.
99. Kemner JE, Starr L, Ciccone PE, Hooper-Wood CG,
Crockett S. Treatment outcomes of OROS ®
methylphenidate compared with atomoxetine in children
with ADHD: a multicenter, randomized, prospective
study. A submission to the National Institute for
Clinical Excellence. Fort Washington, PA: McNeil
Consumer and Speciality Pharmaceuticals; 2004.
100. Pliszka SR, Browne RG, Olvera RL, Wynne SK.
A double-blind, placebo-controlled study of
Adderall and methylphenidate in the treatment of
attention-deficit/hyperactivity disorder. J Am Acad
Child Adolesc Psychiatry 2000;39:619–26.
101. Zeiner P. Do the beneficial effects of extended
methylphenidate treatment in boys with attentiondeficit
hyperactivity disorder dissipate rapidly
during placebo treatment? Nord J Psychiatry
1999;53:55–66.
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 23
102. Albaret JM, Soppelsa R, Marquet-Doleac J.
Interest of the Matching Figure Test in the
diagnostic of the impulsivity component in the
attention deficit/hyperactivity disorder:
comparative study. Approche Neuropsychologique des
Apprentissages chez l’Enfant 2000;12:98–102.
103. Jensen PS. Fact versus fancy concerning the
multimodal treatment study for attention-deficit
hyperactivity disorder. Can J Psychiatry
1999;44:975–80.
104. Taylor E. Development of clinical services for
attention-deficit/hyperactivity disorder. Arch Gen
Psychiatry 1999;56:1097–9.
105. Moderators and mediators of treatment response
for children with attention-deficit/hyperactivity
disorder: the Multimodal Treatment Study of
children with attention-deficit/hyperactivity
disorder. Arch Gen Psychiatry 1999;56:1088–96.
106. Jensen PS, Hinshaw SP, Kraemer HC, Lenora N,
Newcorn JH, Abikoff HB, et al. ADHD
comorbidity findings from the MTA study:
comparing comorbid subgroups. J Am Acad Child
Adolesc Psychiatry 2001;40:147–58.
107. Jensen P, Hinshaw S, Swanson J, Greenhill L,
Conners C, Arnold L, et al. Findings from the
NIMH multimodal treatment study of ADHD
(MPA): implications and applications for primary
care providers. J Dev Behav Pediatr 2001;22:60–73.
108. Vitiello B, Severe J, Greenhill L, Arnold L,
Abikoff H, Bukstein O, et al. Methylphenidate
dosage for children with ADHD over time under
controlled conditions: lessons from the MTA. J Am
Acad Child Adolesc Psychiatry 2001;40:188–96.
109. Greenhill LL, Swanson JM, Vitiello B, Davies M,
Clevenger W, Wu M, et al. Impairment and
deportment responses to different
methylphenidate doses in children with ADHD:
the MTA titration trial. J Am Acad Child Adolesc
Psychiatry 2001;40:180–7.
110. Rieppi R, Greenhil lLL, Ford RE, Chuang S,
Wu M, Davies M, et al. Socioeconomic status as a
moderator of ADHD treatment outcomes. J Am
Acad Child Adolesc Psychiatry 2002;41:269–77.
111. Arnold LE, Elliot M, Sachs L, Bird H,
Kraemer HC, Wells KC, et al. Effects of ethnicity
on treatment attendance, stimulant response/dose,
and 14-month outcome in ADHD. J Consult Clin
Psychol 2003;71:713–27.
112. Galanter CA, Carlson GA, Jensen PS,
Greenhill LL, Davies M, Li W, et al. Response to
methylphenidate in children with attention deficit
hyperactivity disorder and manic symptoms in the
multimodal treatment study of children with
attention deficit hyperactivity disorder titration
trial. J Child Adolesc Psychopharmacol
2003;13:123–36.
137